$120.85$150.99
Prepare to embark on a sensory journey with the Bosco Apple, a fruit that transcends the ordinary and promises an unparalleled taste experience. These apples are nothing short of nature’s masterpiece, celebrated for their distinctive blend of flavors and their captivating visual allure.
Availability: In Stock
Subscribe to out newsletter today to receive latest news administrate cost effective for tactical data.
₹390
INTRODUCTION GEMFOS 35MG TABLET contains Risedronate , which belongs to a group of medicines called Bisphosphonates, which are used to manage bone diseases. It is used to manage osteoporosis in postmenopausal women, increase bone mass in men with osteoporosis, an...
GEMFOS 35MG TABLET contains Risedronate , which belongs to a group of medicines called Bisphosphonates, which are used to manage bone diseases. It is used to manage osteoporosis in postmenopausal women, increase bone mass in men with osteoporosis, and manage osteoporosis in men and women that is caused by treatment with steroid medicine such as prednisone. It is also used to manage Paget’s disease of the bone in men and women.
Osteoporosis is a bone disease that develops when bone mineral density and bone mass decrease or when the quality or structure of bone changes. This can lead to a decrease in bone strength, which can increase the risk of fracture (broken bone).
During postmenopausal osteoporosis, the bones become weaker, more fragile, and more likely to break after a fall or strain. Paget’s disease is a chronic bone disorder that results in enlarged, deformed bones due to excessive breakdown and formation of bone tissue that can cause bones to weaken and may result in bone pain, arthritis, deformities, or fracture.
Before taking this medicine, tell your doctor if you have ever had heart disease or liver problems. GEMFOS 35MG TABLET is not recommended in patients with severe kidney diseases and low blood calcium levels. Consult your doctor for advice.
GEMFOS 35MG TABLET is not recommended for use in pregnant or breastfeeding women. Consult your doctor before taking it.
GEMFOS 35MG TABLET is not recommended for use in children and adolescents under 18 years of age. Consult your doctor before taking it.
The most common side effects of taking GEMFOS 35MG TABLET are indigestion, nausea, stomach pain or discomfort, constipation, feelings of fullness, bloating, diarrhea, pain in your bones, muscles, or joints, and headache. Consult your doctor if any of the side effects worsen.
To manage:
GEMFOS 35MG TABLET works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures).
Always take GEMFOS 35MG TABLET before food in an upright position (you may sit or stand) to avoid heartburn or as advised by your doctor. Swallow the tablet with a glass of water. Do not crush or chew the medicine. Do not lie down for 30 minutes after taking your tablet. Your doctor will decide the correct dose and duration for you depending on your age, body weight, and disease condition. Do not stop taking GEMFOS 35MG TABLET without consulting your doctor, as you may begin to lose bone mass.
Stop taking GEMFOS 35MG TABLET and consult your doctor immediately if you experience any of the following:
Include fiber-rich foods in your diet, such as fresh fruits, vegetables, and whole-grain cereals, and drink plenty of fluids. Exercise more regularly and stay active. Contact your doctor if constipation persists.
Drink lots of fluids, such as water or fruit juices, to keep yourself hydrated. Do not take any medicine on your own to treat diarrhea. Contact your doctor if your diarrhea does not improve.
Rest and relax. Drink plenty of fluids, such as water or ORS (Oral Rehydrating Solution) and apply a pain-relieving balm to the head if necessary. Contact your doctor if your headache does not improve.
Eat smaller and more frequent meals. Eat and drink slowly, and exercise regularly. Contact your doctor if indigestion persists.
Take GEMFOS 35MG TABLET, with or just after a meal. Stick to simple meals. Avoid eating oily or spicy food. Contact your doctor if your nausea does not improve.
Avoid hot baths because hot water can irritate your skin further. Do not scratch the affected area. Use sunscreen and wear protective clothing while going outside. Use unscented moisturizers to soothe and hydrate the affected area. Contact your doctor if your rashes worsen.
Try to rest and relax. You can eat and drink slowly or have smaller and more frequent meals. Applying a heat pad or covered hot water bottle to your stomach may also help. If the pain still persists, speak to your doctor.
GEMFOS 35MG TABLET is not recommended for use by pregnant women. Consult your doctor before taking it.
GEMFOS 35MG TABLET is not recommended for use by breastfeeding women. Consult your doctor before taking it.
GEMFOS 35MG TABLET does not affect your ability to drive or operate machines.
Consumption of alcohol is not recommended during treatment with GEMFOS 35MG TABLET.
GEMFOS 35MG TABLET is not recommended for patients with severe kidney diseases. Consult your doctor for advice.
Do not take GEMFOS 35MG TABLET if you are allergic to risedronate or any other ingredients in this medicine.
GEMFOS 35MG TABLET is not recommended for use in children and adolescents under 18 years of age, as safety and efficacy have not been established. Consult your doctor before taking it.
GEMFOS 35MG TABLET should be used with caution with elderly patients. Consult the doctor before taking GEMFOS 35MG TABLET.
GEMFOS 35MG TABLET is not recommended for use if you:
Before taking GEMFOS 35MG TABLET, inform your doctor if you:
A. Drug-Drug Interactions:
Before taking GEMFOS 35MG TABLET, inform your doctor if you are taking any of the following medicines:
B. Drug-Food interactions:
Take food and drinks (other than plain water) at least 30 minutes after taking GEMFOS 35MG TABLET.
Overdosage:
If you or someone else accidentally takes too much of GEMFOS 35MG TABLET, drink one full glass of milk and consult your doctor immediately.
| Drug | : | Risedronate |
| Pharmacological Category | : | Bisphosphonates |
| Therapeutic Indication | : | Osteoporosis, Paget’s disease of bone |
| Dosage Forms | : | Tablet |
A: GEMFOS 35MG TABLET is not recommended for use by pregnant women. Inform your doctor before taking this medicine if you are pregnant, think you may be pregnant, or are planning to have a baby.
A: No, GEMFOS 35MG TABLET is not recommended for patients with severe kidney diseases. Before taking this medicine, consult your doctor for advice.
A: Take the GEMFOS 35MG TABLET at least 30 minutes before the first food, drink (other than plain water), or other medicine of the day.
A: Always take GEMFOS 35MG TABLET before food in an upright position (you may sit or stand) to avoid heartburn or as advised by your doctor. Swallow the tablet with a glass of water. Do not crush or chew the medicine. Do not lie down for 30 minutes after taking GEMFOS 35MG TABLET. Your doctor will decide the correct dose and duration for you depending on your age, body weight, and disease condition.
A: If you have forgotten to take GEMFOS 35MG TABLET on your chosen day, take it on the day you remember. Return to taking one tablet once a week on the day the tablet is normally taken. Do not take a double dose to make up for a forgotten dose.
1. KD Tripathi. Drugs Affecting Calcium Balance. Essentials of Medical Pharmacology. Seventh Edition,2013. Page - 345.
2. Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. Page - 3415-3417.
3. P Geusens 1, M McClung. Review of risedronate in the treatment of osteoporosis. NIH: National Library of Medicine, National center of biotechnology Information Pubmed.gov. Dec 2001. [Accessed on 7th February 2024] https://pubmed.ncbi.nlm.nih.gov/11825332/
4. Procter & Gamble Pharmaceuticals, Inc,1998; U.S. Food & Drug Administration; [Revised in Jul 2009] [Accessed on 7th February 2024] https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf
5. APL Swift Services (Malta) Limited. Electronic Medicines Compendium (EMC) U.K [Revised in October 2020] [Accessed on 7th February 2024] https://www.medicines.org.uk/emc/files/pil.3028.pdf
6. McDermott Laboratories Limited. Health Products Regulatory Authority (HPRA). [Revised in February 2015] [Accessed on 7th February 2024] https://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA0577-167-001_25042016091039.pdf
Written By Dr. N. Sai Swaroop, Pharm.D
Last updated on 08 Feb 2024 | 03:43 PM(IST)